<DOC>
	<DOCNO>NCT00526760</DOCNO>
	<brief_summary>Evaluate efficacy safety dexmedetomidine long term administration ICU patient require 24 hour sedation .</brief_summary>
	<brief_title>Long-term Clinical Study Evaluating Safety Efficacy Dexmedetomidine ICU Subjects</brief_title>
	<detailed_description>According current dexmedetomidine indication , duration dexmedetomidine administration limit within 24 hour . However , strong demand medical specialist continue administration dexmedetomidine excess 24 hour medical practice large number patient require sedation 24 hour ICU . To meet clinical demand , plan conduct phase III long-term administration study dexmedetomidine obtain approval infusion dexmedetomidine 24 hour .</detailed_description>
	<mesh_term>Dexmedetomidine</mesh_term>
	<criteria>1 . Patient legally acceptable representative ( acceptable Institutional Review Board/Ethics Committee ) sign date Informed Consent study fully explain . 2 . Patient male female , least 20 year age . 3 . In case surgical ICU patient , condition American Society Anesthesiologists ( ASA ) I III Class preoperatively . 4 . Patient mechanical ventilation anticipate require sedation 24 hour follow surgery . 5 . If patient female child bear potential , nonpregnant , lactate . 1 . Patient serious central nervous system ( CNS ) trauma . 2 . Patient require use neuromuscular blocking agent admission ICU , except insertion endotracheal tube . 3 . Patient hospitalized drug overdose within last 30 day . 4 . Patient alpha2 antagonist alpha2 agonist contraindicate . 5 . Patient currently treat treat within last 30 day alpha2 agonist antagonist . 6 . Patient participate trial experimental drug within 30 day prior admission ICU . 7 . Terminally ill patient , whose life duration expectancy around 30 day . 8 . Patient consider unable undergo procedure require protocol . 9 . Patient excessive bleeding likely require surgery . 10 . In Investigator 's opinion , patient symptom factor , might increase risk patient preclude obtain satisfactory study data .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Dexmedetomidine , Sedation , Long-term , Phase 3</keyword>
</DOC>